278 completed, 80 terminated, 45 unknown, 14 withdrawn. 274 Phase 2, 138 Phase 1, 42 Phase 3, 10 Not applicable, 7 Phase 4.
Follow Erlotinib: new trials by email Literature Review of Erlotinib trials Research Report on Erlotinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Epidermal Growth Factor Receptor Inhibition for Keratinopathies Erlotinib - Epidermolytic Ichthyosis, Palmoplantar Keratoderma | Phase 1 / Phase 2 | Not yet recruiting | Northwestern University | 44 | 2027-07-01 | 2026-08-03 |
| Erlotinib in Combination With Select Tyrosine Kinase Inhibitors in Adult Patients With Advanced Solid Tumors Erlotinib, Lenvatinib, Axitinib - Neoplasms | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2025-07-15 | 2025-07-16 | |
| Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxel Gemcitabine, Nab paclitaxel, Erlotinib - Pancreatic Adenocarcinoma, Metastatic Pancreatic Cancer | Phase 1 / Phase 2 | Recruiting | UNC Lineberger Comprehensive Cancer Center | 104 | 2025-02-06 | 2026-04-23 |
| A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. lorlatinib, crizotinib, brigatinib - Non-Small Cell Lung Cancer | Completed | Pfizer | 5279 | 2023-06-23 | 2025-03-30 | |
| Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications BBI-355, Erlotinib, Futibatinib - Triple Negative Breast Cancer (TNBC), High Grade Serous Ovarian Carcinoma | Phase 1 | Terminated | Boundless Bio, Inc. | 85 | 2023-03-24 | 2026-08-19 |
| A Phase II Stydy of Bevacizumab Plus Erlotinib in Patients for Krebs Cycle Altered Cancer bevacizumab, erlotinib - Solid Tumors, Advanced Solid Tumors | Phase 2 | Unknown | Asan Medical Center | 32 | 2023-01-02 | 2023-06-15 |
| KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II Alectinib, Atezolizumab, Erlotinib - Solid Tumor, Advanced Solid Tumor | Active not recruiting | Seoul National University Bundang Hospital | 1000 | 2022-09-28 | 2026-09-30 | |
| Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer Atezolizumab, Bevacizumab, Biopsy Procedure - Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 65 | 2022-06-10 | 2026-10-26 |
| Pemetrexed in Combination With Erlotinib as a Salvage Treatment in Patients With Metastatic Biliary Tract Cancer (BTC) Who Failed Gemcitabine Containing Chemotherapy: A Phase II Single Arm Prospective Study Pemetrexed 500 MG, Erlotinib - Biliary Tract Cancer | Phase 2 | Unknown | Samsung Medical Center | 44 | 2021-07-09 | 2022-06-15 |
| The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy Erlotinib, Trastuzumab, Trastuzumab emtansine - Breast Cancer, Gastrointestinal Cancer | Phase 2 | Unknown | Fondazione per la Medicina Personalizzata | 400 | 2020-10-07 | 2023-10-03 |
| Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study Bevacizumab, Erlotinib, Gefitinib - NSCLC | Unknown | Guangdong Association of Clinical Trials | 272 | 2020-10-07 | 2020-10-20 | |
| Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC Almonertinib, Erlotinib, Cisplatin - Non-Small Cell Lung Cancer Stage IIIA | Phase 2 | Unknown | The First Affiliated Hospital of Guangzhou Medical University | 168 | 2020-10-01 | 2020-07-02 |
| ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling Alectinib, Atezolizumab, Avelumab - Cancer, Tumors | Phase 2 | Recruiting | Ulrik Lassen | 300 | 2020-08-24 | 2025-07-25 |
| A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation GDC-6036, Atezolizumab, Cetuximab - Non-Small Cell Lung Cancer, Colorectal Cancer | Phase 1 | Active not recruiting | Genentech, Inc. | 498 | 2020-07-29 | 2026-08-28 |
| PD-1 Immune Checkpoint Inhibitors and Immune-Related Adverse Events: a Cohort Study PD-1 inhibitor, Chemotherapy Drugs, Cancer - Carcinoma, Non-Small-Cell Lung, Immune-Related Adverse Events | Unknown | Sungkyunkwan University | 4724 | 2020-07-01 | 2020-05-28 | |
| Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial Abemaciclib, Abiraterone, Afatinib - Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8 | Phase 1 | Terminated | OHSU Knight Cancer Institute | 2 | 2020-04-01 | 2024-03-04 |
| Brazilian Lung Immunotherapy Study Alectinib, Pembrolizumab, Nivolumab - Lung Neoplasm | Phase 2 | Completed | Hospital Israelita Albert Einstein | 154 | 2020-01-01 | 2023-10-11 |
| A Study of LY3499446 in Participants With Advanced Solid Tumors With KRAS G12C Mutation LY3499446, Abemaciclib, Cetuximab - Advanced Solid Tumor, Non-Small Cell Lung Cancer | Phase 1 / Phase 2 | Terminated | Eli Lilly and Company | 5 | 2019-11-28 | 2021-11-24 |
| First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases AZD3759, Erlotinib, Gefitinib - Non-small Cell Lung Cancer, EGFR Gene Mutation | Phase 2 / Phase 3 | Completed | Alpha Biopharma (Jiangsu) Co., Ltd. | 492 | 2018-10-29 | 2025-09-10 |
| A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site Alectinib, Vismodegib, Ipatasertib - Cancer of Unknown Primary Site | Phase 2 | Completed | Hoffmann-La Roche | 529 | 2018-07-10 | 2025-11-19 |
Showing 20 of 432. Sign in to see all of them.
Carcinoma, Non-Small-Cell Lung (185) · Lung Neoplasms (61) · Pancreatic Neoplasms (41) · Neoplasms (38) · Neoplasm Metastasis (22) · Squamous Cell Carcinoma of Head and Neck (17) · Head and Neck Neoplasms (16) · Brain Neoplasms (15) · Breast Neoplasms (14) · Carcinoma, Hepatocellular (13) · Glioblastoma (12) · Gliosarcoma (11) · Adenocarcinoma of Lung (9) · Rectal Neoplasms (9) · Carcinoma, Renal Cell (8)
National Cancer Institute (NCI) (51) · Hoffmann-La Roche (32) · M.D. Anderson Cancer Center (31) · Eli Lilly and Company (11) · SCRI Development Innovations, LLC (9) · Pfizer (8) · Massachusetts General Hospital (6) · Memorial Sloan Kettering Cancer Center (6) · Merck Sharp & Dohme LLC (6) · Dana-Farber Cancer Institute (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · OSI Pharmaceuticals (5) · Daiichi Sankyo (4) · Fox Chase Cancer Center (4) · Genentech, Inc. (4)
United States (278) · South Korea (48) · Spain (43) · Italy (41) · France (39) · Canada (36) · Germany (35) · China (32) · United Kingdom (32) · Netherlands (28) · Taiwan (28) · Belgium (24) · Poland (21) · Hungary (19) · Australia (18)
Helena Yu, MD (4) · Jennifer J. Wheler, MD (3) · John D. Hainsworth, MD (3) · Philip Philip (3) · Arun Rajan, M.D. (2) · Aung Naing, MD (2)
PMID 33067126, PMID 22586319, PMID 23442309, PMID 37794220, PMID 39863139, PMID 14520092, PMID 17470864, PMID 18056187, PMID 18272024, PMID 18955445, PMID 19047285, PMID 19075262, PMID 19201650, PMID 19415121, PMID 19523815, PMID 19616281, PMID 19965914, PMID 20089114, PMID 20573926, PMID 20630061, PMID 20632579, PMID 20837357, PMID 21135251, PMID 21282542, PMID 21358293, PMID 21439671, PMID 21550561, PMID 21705281, PMID 21783417, PMID 21953248, PMID 21985945, PMID 22160298, PMID 22210086, PMID 22253412, PMID 22285168, PMID 22440336, PMID 22643560, PMID 22750258, PMID 22773551, PMID 22778317, PMID 22791662, PMID 22878749, PMID 22949150, PMID 22972589, PMID 23032625, PMID 23102811, PMID 23154555, PMID 23182701, PMID 23308140, PMID 23384718
2014 (5), 2005 (4), 2009 (4), N01CM62201 (4), U10CA032102 (4), 2004 (3), 2008 (3), 2015 (3), P30CA014599 (3), P30CA015083 (3), P30CA093373 (3), U01CA070095 (3), U10CA021115 (3), U10CA031946 (3), N01CM17104 (2)